Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 06

1363P - An AI-derived tool to pre-screen lung cancer candidates for clinical trials

Date

14 Sep 2024

Session

Poster session 06

Topics

Cancer Intelligence (eHealth, Telehealth Technology, BIG Data)

Tumour Site

Presenters

Mihaela Aldea

Citation

Annals of Oncology (2024) 35 (suppl_2): S802-S877. 10.1016/annonc/annonc1602

Authors

P. Rolland1, L. Zullo2, A. Poplu1, S. Simon3, A. Djarallah1, M. Wartelle4, L. Chutto1, B. Vignal1, F. Lion4, S. Platano1, A. Gazzah5, C. Robert6, F. André3, F. Barlesi7, S. Michiels8, C. Baldini5, C.P. Massard9, F. Le Ouay1, B. Besse7

Author affiliations

  • 1 Data Science, Lifen, 75008 - Paris/FR
  • 2 Department Of Cancer Medicine, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 3 Medical Oncology Department, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 4 Epidemiology And Biostatistics, Gustave Rousy, 94800 - Villejuif/FR
  • 5 Drug Development Department, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 6 Dermatology Department, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 7 Medical Oncology, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 8 Team Oncostat, Cesp, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 9 Ditep Department, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1363P

Background

Patient selection in clinical trials is crucial but challenging, traditionally dependent on clinician-led identification that might overlook potential participants. We suggest an artificial intelligence (AI)-enhanced approach for institutional patient screening to improve trial enrolment.

Methods

This retrospective study analysed advanced lung cancer patients who attended Gustave Roussy between Feb 2021-Dec 2023. We automated the extraction and structuring of 83 variables from unstructured patient notes, including demographic, disease characteristics (histology, PD-L1 status, molecular and metastatic status), comorbidities, treatment history, and life status. Automated Data Entry (ADE) used advanced language model techniques, with prompt engineering and tailored few-shot examples, compared against Manual Data Entry (MDE) for accuracy. The primary goal was to assess ADE's accuracy of capturing data critical for determining trial eligibility. The method was tested to identify candidates for a phase I trial targeting advanced lung cancer patients with SMARCA4 alterations, pre-treated with ≥1 line of systemic therapy, and an ECOG status of 0-1.

Results

Of 1,057 patients screened, the median completeness of data per patient was 96.7%, with a processing time of 3 minutes per patient. Among 137 patients with both ADE and MDE, ADE achieved 96% accuracy. Of the 39 patients with SMARCA4 alterations, ADE identified 35 (90%), compared to 25 (64%) by MDE. ADE found 21 living patients with SMARCA4 alterations, 15 of whom had metastatic disease. It further identified 13 patients treated in advanced settings, including 8 with progression on ≥one line of therapy (potential candidates) and 5 on first-line chemo-immunotherapy without progression (potential waiting list candidates). After integrating the latest ECOG status, ADE accurately pre-screened 7 patients for the main criteria and 5 for the waiting list.

Conclusions

The AI-driven ADE method is feasible for pre-screening of lung cancer patients for precision medicine trials, achieving over 90% accuracy in identifying main eligibility criteria. This scalable approach could ensure more precise patient selection and optimize clinical trial matching.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

B. Besse, Institut Gustave Roussy, Villejuif, France.

Funding

Has not received any funding.

Disclosure

M. Aldea: Financial Interests, Personal and Institutional, Research Funding: AstraZeneca, Sandoz, Amgen. P. Rolland, A. Poplu, A. Djarallah, L. Chutto, B. Vignal, S. Platano: Financial Interests, Personal, Affiliate: Lifen. F. Le Ouay: Financial Interests, Personal, Ownership Interest: Lifen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.